Nome |
# |
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities, file e31e124c-0965-987f-e053-3705fe0a095a
|
426
|
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer., file e31e124d-7808-987f-e053-3705fe0a095a
|
317
|
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management, file e31e124d-7fd3-987f-e053-3705fe0a095a
|
313
|
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB), file e31e124d-7671-987f-e053-3705fe0a095a
|
293
|
Immune characterization of breast cancer metastases: prognostic implications., file e31e124d-5d08-987f-e053-3705fe0a095a
|
264
|
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer, file e31e124d-9653-987f-e053-3705fe0a095a
|
250
|
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial., file e31e124d-7fd1-987f-e053-3705fe0a095a
|
236
|
Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood, file e31e124c-0052-987f-e053-3705fe0a095a
|
227
|
MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma, file e31e124d-9655-987f-e053-3705fe0a095a
|
223
|
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial ., file e31e124d-cbc5-987f-e053-3705fe0a095a
|
202
|
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing, file e31e124b-5969-987f-e053-3705fe0a095a
|
194
|
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus, file e31e124d-734b-987f-e053-3705fe0a095a
|
193
|
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer., file e31e124d-ce9b-987f-e053-3705fe0a095a
|
174
|
Triple-negative breast cancer: current management and future options., file e31e124e-1a5e-987f-e053-3705fe0a095a
|
170
|
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA, file e31e124d-35ff-987f-e053-3705fe0a095a
|
166
|
Controversies of chemotherapy for the treatment of metastatic breast cancer., file e31e124e-154d-987f-e053-3705fe0a095a
|
160
|
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis, file e31e124d-7fcf-987f-e053-3705fe0a095a
|
151
|
Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial., file e31e124d-cb11-987f-e053-3705fe0a095a
|
135
|
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY), file e31e124d-33f2-987f-e053-3705fe0a095a
|
122
|
Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial, file e31e124f-ec08-987f-e053-3705fe0a095a
|
112
|
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y), file e31e124e-a41a-987f-e053-3705fe0a095a
|
110
|
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici, file e31e124a-97dc-987f-e053-3705fe0a095a
|
79
|
LOCAL RECURRENCE AFTER NEO-ADJUVANT CHEMOTHERAPY AND BREAST CONSERVING SURGERY, file e31e124d-2092-987f-e053-3705fe0a095a
|
66
|
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER, file e31e124d-351c-987f-e053-3705fe0a095a
|
62
|
Device for cell culture, file e31e124a-9d0c-987f-e053-3705fe0a095a
|
57
|
Mesenchymal progenitors aging highlights a mir-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis, file e31e124c-08f7-987f-e053-3705fe0a095a
|
40
|
Evaluation of thrombopoiesis kinetics by measurement of reticulated platelets and CD34+ cell subsets in patients with solid tumors following high dose chemotherapy and autologous peripheral blood progenitor cell support., file e31e124e-13ed-987f-e053-3705fe0a095a
|
39
|
MANAGEMENT OF ADVANCED BREAST CANCER: HOW TO INTEGRATE SCIENTIFIC DATA AND CLINICAL JUDGMENT, file e31e124d-223a-987f-e053-3705fe0a095a
|
35
|
PIK3CA MUTATIONS IN HER2-POSITIVE BREAST CANCER PATIENTS ENROLLED IN THE ADJUVANT RANDOMIZED SHORT-HER STUDY., file e31e124e-9724-987f-e053-3705fe0a095a
|
35
|
41. HER2+ EARLY BREAST CANCER: DO WE HAVE ALL THE NECESSARY ANSWERS?, file e31e124d-223c-987f-e053-3705fe0a095a
|
32
|
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY, file e31e124d-3704-987f-e053-3705fe0a095a
|
31
|
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS, file e31e124d-30ab-987f-e053-3705fe0a095a
|
30
|
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO, file e31e124d-30e4-987f-e053-3705fe0a095a
|
29
|
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study., file e31e124f-89bb-987f-e053-3705fe0a095a
|
29
|
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial, file e31e1250-9101-987f-e053-3705fe0a095a
|
29
|
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA, file e31e124d-3016-987f-e053-3705fe0a095a
|
23
|
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS, file e31e124d-3017-987f-e053-3705fe0a095a
|
22
|
TREATMENT OF EARLY HER2+ BREAST CANCER: ACHIEVEMENTS AND UNMET NEEDS, file e31e124d-2110-987f-e053-3705fe0a095a
|
20
|
TAILORED MANAGEMENT OF ADVANCED BREAST CANCER: IS IT WORTH TO TAKE A BIOPSY OF METASTATIC SITES?, file e31e124d-223e-987f-e053-3705fe0a095a
|
20
|
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE, file e31e124d-3522-987f-e053-3705fe0a095a
|
18
|
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy., file 3171ff3b-9c3a-4cef-94ca-d122ec5822e0
|
16
|
Primary systemic treatment of operable breast cancer with targeted agents, file e31e124d-32ca-987f-e053-3705fe0a095a
|
16
|
VALUTAZIONE DEL RISCHIO DI TOSSICITA’ CARDIACA DI TRASTUZUMAB IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO IN TRATTAMENTO ADIUVANTE, file e31e124d-3519-987f-e053-3705fe0a095a
|
16
|
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design., file 50125a79-d15f-4420-845a-4cba99984d1a
|
15
|
CHER-LOB: PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER – PRELIMINARY SAFETY REPORT WITH FOCUS ON CARDIAC TOLERABILITY, file e31e124d-38aa-987f-e053-3705fe0a095a
|
14
|
Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide, file a6a3589d-4ddd-44e5-a9ef-7c7ce3bfc294
|
13
|
Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC)., file d230e624-2b64-483e-9d21-b703da38ed62
|
10
|
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY, file e31e124d-3075-987f-e053-3705fe0a095a
|
10
|
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial, file 1264406e-f2c7-4461-a784-fb6ee90d3d5f
|
9
|
Randomized controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from Mario Negri Institute of Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group., file 8103b041-9b3a-4467-bd2e-6598d7b76959
|
7
|
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma - Results from the Gruppo Oncologico Nord Ovest randomized trial, file 4ad83630-2aa3-40ae-b6b0-34e1c313a502
|
6
|
Pattern of distant relapse according to intrinsic molecular subtype in patients with HER2-positive breast cancer: a combined analysis of ShortHER, CherLOB, and two institutional cohorts, file bf213bec-1647-46b0-a203-20d776629dcd
|
6
|
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas, file e31e124b-ffe1-987f-e053-3705fe0a095a
|
6
|
Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety, file 2b111427-83d8-451a-84d8-ea5668bcec0f
|
5
|
Optimizing Bisphosphonate therapy in Oncology, file b49920bb-1658-454a-947c-65f70a425abf
|
4
|
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy, file b90eb385-8b45-4964-9e43-ab89a237165d
|
4
|
MSC and Tumors: Homing, Differentiation and Secretion Influence The Therapeutic Potentials, file e31e124c-033f-987f-e053-3705fe0a095a
|
4
|
Muiticentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer, file ea68bfc8-2760-4af4-8e5f-bf4b2f296fda
|
4
|
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer, file 39f0de05-ed6f-4a67-97e0-9a8ce7eed0c5
|
3
|
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab, file dc88f2b3-59fc-468a-aee9-b7bc0c5becc2
|
3
|
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC), file c0455a7d-75be-4e41-a009-fe11d544c62d
|
2
|
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer, file e31e124a-967d-987f-e053-3705fe0a095a
|
2
|
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria, file e31e124a-97da-987f-e053-3705fe0a095a
|
2
|
Neoadjuvant treatment with Single – Agent Cetuximab Followed by 5-Fu, Cetuximab, and Pelvic Radiotherapy: A Phase II Study in Locally Advanced Rectal Cancer., file e31e124a-9c6a-987f-e053-3705fe0a095a
|
2
|
Heterogeneity of multipotent mesenchimal stromal cells: from stromal cells to stem cells and viceversa, file e31e124a-9f49-987f-e053-3705fe0a095a
|
2
|
Laparoscopic approach of gastric gastrointestinal stromal tumors (GISTs): Is it still a courageous choice? Report of two cases, file e31e124a-9f52-987f-e053-3705fe0a095a
|
2
|
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies., file e31e124a-aba1-987f-e053-3705fe0a095a
|
2
|
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma, file e31e124a-acfd-987f-e053-3705fe0a095a
|
2
|
Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact, file e31e124c-0494-987f-e053-3705fe0a095a
|
2
|
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study, file edcdd8de-215f-49c6-9abb-0985573f6c0d
|
2
|
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study, file f800e220-a4de-4bda-9cef-86eb5303726e
|
2
|
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients, file ff5e87e6-33f4-4094-9b20-ed07baf00572
|
2
|
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma, file 8e9fbe70-d335-4fe1-96b8-779cb8a1c805
|
1
|
Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM, file e31e124a-9519-987f-e053-3705fe0a095a
|
1
|
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry, file e31e124a-9c7a-987f-e053-3705fe0a095a
|
1
|
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy, file e31e124a-9f5a-987f-e053-3705fe0a095a
|
1
|
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of After-6 protocol 1, file e31e124a-a2cd-987f-e053-3705fe0a095a
|
1
|
Gastrointestinal stromal tumor and other primary metachronous and synchronous neoplasms as a suspicious criterion for syndromic setting, file e31e124a-a2cf-987f-e053-3705fe0a095a
|
1
|
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer, file e31e124a-af0f-987f-e053-3705fe0a095a
|
1
|
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis., file e31e124a-af9d-987f-e053-3705fe0a095a
|
1
|
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study, file e31e124b-2edd-987f-e053-3705fe0a095a
|
1
|
Timing for starting second line therapy in recurrent ovarian cancer., file e31e124b-2ee2-987f-e053-3705fe0a095a
|
1
|
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis, file e31e124b-3439-987f-e053-3705fe0a095a
|
1
|
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer, file e31e124d-766b-987f-e053-3705fe0a095a
|
1
|
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study., file e31e124d-80fe-987f-e053-3705fe0a095a
|
1
|
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion., file e31e124d-d8bd-987f-e053-3705fe0a095a
|
1
|
Totale |
5.343 |